Centre For Research Excellence In Cervical Cancer Control (C4)
Funder
National Health and Medical Research Council
Funding Amount
$2,486,383.00
Summary
Cervical cancer remains common globally despite over 50 years of Pap testing. Australia led the world in HPV vaccination and in 2017 will be the first to deliver a national screening program based on HPV testing. Our CRE, led by cervical cancer prevention experts at CCNSW,VCS, and Kirby, will marry cross-disciplinary research and evaluation of HPV vaccination and screening to provide solid evidence about these new approaches with a view to ultimately reducing the global burden of this cancer.
Developing A Scalable, Woman-centred Model For Cervical Cancer Screening In Vulnerable Women In India
Funder
National Health and Medical Research Council
Funding Amount
$1,330,369.00
Summary
Cervical cancer is a devastating but preventable disease and 1 in 5 cases of cervical cancer in the world occur in India. We will work with women, communities, and health services in two States of India (Tamil Nadu and Mizoram) to design a woman friendly approach to prevent cervical cancer. This project brings together international and Indian experts to overcome current barriers to cervical screening by using a newer, more effective way of screening to reach underserved women and save lives.
HPV-based Testing And Treatment For The Elimination Of Cervical Cancer In Papua New Guinea (HPVTATE)
Funder
National Health and Medical Research Council
Funding Amount
$1,590,166.00
Summary
Building on the innovative cervical screening model that we successfully designed and delivered in partnership with provincial health authorities in urban primary care settings in PNG, the overarching aim of the proposed study is to determine the reach, effectiveness, cost-effectiveness, acceptability and scalability of HPV-based testing and treatment for the elimination of cervical cancer (HPVTATE) among women in rural and remote communities in Papua New Guinea.
Effectiveness And Cost-Effectiveness Of HPV Vaccination And HPV-Based Cervical Cancer Screening Strategies In China
Funder
National Health and Medical Research Council
Funding Amount
$420,692.00
Summary
In the absence of preventative initiatives, up to 187,000 women will develop cervical cancer in China every year. However, the disease is preventable using human papillomavirus (HPV) vaccination and primary HPV screening. Building on previous work, we will evaluate the most effective and cost-effective options for cervical cancer prevention, in order to provide an comprehensive evidence base for China’s health decision-makers.
Optimising Cervical Screening After The Introduction Of HPV Vaccination In Australia: Modelling Of Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$316,089.00
Summary
This research project will aid decision-making about how best to perform cervical screening in Australia after the introduction of vaccination against the human papillomavirus (or HPV). The project will use computer simulation techniques to explore different scenarios for vaccination and screening and to determine the optimal approach. This project involves a group of international collaborators with expertise in a number of areas including cancer epidemiology, screening for cancer, and computer ....This research project will aid decision-making about how best to perform cervical screening in Australia after the introduction of vaccination against the human papillomavirus (or HPV). The project will use computer simulation techniques to explore different scenarios for vaccination and screening and to determine the optimal approach. This project involves a group of international collaborators with expertise in a number of areas including cancer epidemiology, screening for cancer, and computer simulation methods. HPV is the virus responsible for the development of cervical cancer, and clinical trials have demonstrated that HPV vaccines administered to adoloescent girls are very effective at preventing disease that might have led to cancer in the future. However, Australia currently has a very effective Pap smear screening program, and in the first phase after the introduction of vaccination it will be important for women to continue being screened as usual. In the long term, HPV vaccination is expected to reduce the need for Pap smears. The research will involve a very detailed simulation of how HPV is transmitted in the Australian population, and how this will change after vaccination. The simulation will address questions of importance for any future public HPV vaccination program, such as whether males should be vaccinated as well as females. The simulation will also be used to determine the optimal starting age and frequency of Pap smears in the future. The outcomes of the research will be very important for policy-makers. In the long term, this research will ensure that the best recommendations are formulated for the timing and frequency of Pap smears after HPV vaccination is introduced.Read moreRead less
Evaluation Of Outcomes And Cost-effectiveness Of Implementing Next Generation Human Papillomavirus (HPV) Vaccination And Associated Primary HPV-based Cervical Cancer Screening Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$697,071.00
Summary
This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new va ....This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new vaccine.Read moreRead less
Evaluation Of Future Cervical Cancer Prevention Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
The overall aim of the project is to use simulation modelling to perform a detailed epidemiologic and economic evaluation of the role of primary HPV DNA testing in Australia in the context of HPV vaccination. The project involves a collaboration with investigators at the National Cancer Institute USA, to analyse data from large studies conducted around the world and to build an accurate simulation of HPV infection and the development of cervical cancer.
Evaluation Of Primary HPV Testing For Cervical Screening In Australia
Funder
National Health and Medical Research Council
Funding Amount
$701,037.00
Summary
The overall aim of the project is to use simulation modelling to perform a detailed evaluation of new approaches to cervical screening in Australia, taking into account the implementation of the National HPV Vaccination Program. The project involves collaboration between Australian researchers and investigators at the National Cancer Institute USA. We will integrate local and international data to lead the world in understanding how cervical screening should best be performed in the context of H ....The overall aim of the project is to use simulation modelling to perform a detailed evaluation of new approaches to cervical screening in Australia, taking into account the implementation of the National HPV Vaccination Program. The project involves collaboration between Australian researchers and investigators at the National Cancer Institute USA. We will integrate local and international data to lead the world in understanding how cervical screening should best be performed in the context of HPV vaccination.Read moreRead less
Developing And Testing A Community-informed Intervention To Increase VIA Cervical Cancer Screening In Eswatini
Funder
National Health and Medical Research Council
Funding Amount
$1,206,528.00
Summary
Eswatini has the highest rate of cervical cancer in the world. Cervical cancer screening is effective at reducing deaths from this disease. However, in Eswatini rates of cervical screening are very low, with one study estimating that only 5% of women had ever undergone screening. This project will explore barriers to cervical screening in Eswatini, and develop and test culturally appropriate strategies to improve participation in cervical screening.